Patents by Inventor Caixia Zang

Caixia Zang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11440931
    Abstract: Provided are a series of crocins compounds and related pharmacological applications thereof in prevention and treatment of Alzheimer's disease. The series of crocins compounds are obtained by taking the Chinese herb, namely Gardenia jasminoides Ellis, as a raw material and separating same by means of various methods. The compounds playing a role in preventing oxidative injury caused by hydrogen peroxide (H2O2) and excitatory amino acid injury caused by L-glutamic acid are screened out by in-vitro cell experiments. The results show that the crocins compounds have good effect in preventing cell injury caused by H2O2 and L-glutamic acid. The compounds have good effect in preventing and treating Alzheimer's disease due to the fact that significant rise of oxidative stress and excitatory amino acid is a key factor for nerve injury in Alzheimer's disease, and have broad development and application prospect.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 13, 2022
    Assignee: Jinan University
    Inventors: Xinsheng Yao, Yang Yu, Dan Zhang, Yang Ni, Xiuqi Bao, Lin Li, CaixĂ­a Zang, Hao Gao, Yuanpeng Zheng
  • Patent number: 10851129
    Abstract: A composition, and a crocins active site extracted from Gardenia jasminoides Ellis, mainly comprising the following ingredients: crocetin di-?-D-gentiobioside, crocetin-?-D-glucopyranosyl-?-D-gentiobioside, crocetin di-?-D-glucopyranoside, 13Z-crocetin di-?-D-gentiobioside, neocrocin B, crocetin mono-?-D-gentiobioside, 13Z-crocetin-8-O-?-D-gentiobioside, 13Z-crocetin-8?-O-?-D-gentiobioside, and crocetin mono-?-D-glucopyranoside. Pharmacological experiment results show that the crocins active site can effectively improve learning and memory injuries in mice induced by scopolamine and amyloid ? protein.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: December 1, 2020
    Assignee: Jinan University
    Inventors: Xinsheng Yao, Dan Zhang, Yang Yu, Xiuqi Bao, Yang Ni, Caixia Zang
  • Publication number: 20190177354
    Abstract: Provided are a series of crocins compounds and related pharmacological applications thereof in prevention and treatment of Alzheimer's disease. The series of crocins compounds are obtained by taking the Chinese herb, namely Gardenia jasminoides Ellis, as a raw material and separating same by means of various methods. The compounds playing a role in preventing oxidative injury caused by hydrogen peroxide (H2O2) and excitatory amino acid injury caused by L-glutamic acid are screened out by in-vitro cell experiments. The results show that the crocins compounds have good effect in preventing cell injury caused by H2O2 and L-glutamic acid. The compounds have good effect in preventing and treating Alzheimer's disease due to the fact that significant rise of oxidative stress and excitatory amino acid is a key factor for nerve injury in Alzheimer's disease, and have broad development and application prospect.
    Type: Application
    Filed: March 16, 2017
    Publication date: June 13, 2019
    Applicant: Jinan University
    Inventors: Xinsheng Yao, Yang Yu, Dan Zhang, Yang Ni, Xiuqi Bao, Lin Li, Caixia Zang, Hao Gao, Yuanpeng Zheng
  • Publication number: 20190112326
    Abstract: A composition, and a crocins active site extracted from Gardenia jasminoides Ellis, mainly comprising the following ingredients: crocetin di-?-D-gentiobioside, crocetin-?-D-glucopyranosyl-?-D-gentiobioside, crocetin di-?-D-glucopyranoside, 13Z-crocetin di-?-D-gentiobioside, neocrocin B, crocetin mono-?-D-gentiobioside, 13Z-crocetin-8-O-?-D-gentiobioside, 13Z-crocetin-8?-O-?-D-gentiobioside, and crocetin mono-?-D-glucopyranoside. Pharmacological experiment results show that the crocins active site can effectively improve learning and memory injuries in mice induced by scopolamine and amyloid ? protein.
    Type: Application
    Filed: March 16, 2017
    Publication date: April 18, 2019
    Inventors: Xinsheng Yao, Dan Zhang, Yang Yu, Xiuqi Bao, Yang Ni, Caixia Zang